Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Asciminib |
Synonyms | |
Therapy Description |
Asciminib (ABL001) is an allosteric inhibitor of BCR-ABL that binds to a unique location outside the ATP binding site, resulting in decreased BCR-ABL kinase activity and reduced tumor growth (Blood Dec 2014, 124 (21) 398). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Asciminib | Scemblix | ABL001|ABL-001 | BCR-ABL Inhibitor 28 | Scemblix (asciminib) is an allosteric inhibitor of BCR-ABL that binds to a unique location outside the ATP binding site, resulting in decreased BCR-ABL kinase activity and reduced tumor growth (PMID: 31543464, PMID: 31826340). Scemblix (asciminib) is FDA approved for use in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) after two or more tyrosine kinase inhibitor treatments, and in adult patients with Ph+ CML in CP harboring ABL1 T315I (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02081378 | Phase I | Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib | A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 5 |
NCT04216563 | Phase II | Asciminib | ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor | Recruiting | USA | 0 |
NCT04666259 | Phase III | Asciminib | Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (AIM4CML) | Recruiting | USA | 0 |
NCT04948333 | Phase III | Asciminib | Asciminib Treatment Optimization in >= 3rd Line CML-CP. | Recruiting | ITA | FRA | ESP | DEU | CAN | AUT | 8 |
NCT05143840 | Phase II | Asciminib Asciminib + Nilotinib | Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | Recruiting | USA | 0 |
NCT04971226 | Phase III | Asciminib Bosutinib Imatinib Dasatinib Nilotinib | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 21 |
NCT03106779 | Phase III | Bosutinib Asciminib | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 19 |
NCT04925479 | Phase Ib/II | Asciminib | Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | Recruiting | USA | ITA | FRA | DEU | 7 |